Aligos Therapeutics, Inc.
No SEC Form 4 filings for $ALGS in the last 30 days.
See all $ALGS insider activity →Aligos Therapeutics (ALGS) stock rose 7.6% in pre-market trading to $6.55, despite a broader market decline. The rally follows recent operational milestones, better-than-expected Q2 2026 earnings, and a completed Phase 2 study enrollment for its hepatitis B treatment. The company's balance sheet was strengthened by a licensing deal. The stock remains below its 52-week high of $13.69.
Aligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improvi
Aligos Therapeutics (ALGS) said it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for Pevifoscorvir sodium for chronic HBV. The therapy received China’s NMPA Breakthrough Therapy Designation. Aligos may earn up to $420M in milestones plus tiered royalties; Amoytop plans to start China development of ALG-170675 later this year.
Over the past 7 days, alphai's AI scored 1 news story mentioning ALGS (Aligos Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ALGS coverage spans mergers & acquisitions, market movers and financial news.
The pre‑open surge suggests short‑term buying pressure but lacks a fresh catalyst.
Near-term focus is funding runway and milestone timing, while the main catalyst is late Q3 2027 topline for B-SUPREME.
The upfront cash and milestone structure de-risks near-term funding while signaling progress toward China clinical development for ALG-170675.
The licensing deal provides immediate liquidity and milestone/royalty upside while preserving most ex-Greater China rights.
Near-term upside bias from non-dilutive cash ($25M) plus accelerated China regulatory pathway (Breakthrough Therapy Designation) for pevifoscorvir sodium.
alphai scores every news story that mentions ALGS with an AI model for sentiment and relevance, and aggregates insider trades from Aligos Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aligos Therapeutics (ALGS) stock rose 7.6% in pre-market trading to $6.55, despite a broader market decline. The rally follows recent operational milestones, better-than-expected Q2 2026 earnings, and a completed Phase 2 study enrollment for its hepatitis B treatment. The company's balance sheet was strengthened by a licensing deal. The stock remains below its 52-week high of $13.69.
1 min readAligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improvi
6 min readAligos Therapeutics (ALGS) said it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for Pevifoscorvir sodium for chronic HBV. The therapy received China’s NMPA Breakthrough Therapy Designation. Aligos may earn up to $420M in milestones plus tiered royalties; Amoytop plans to start China development of ALG-170675 later this year.
3 min readAligos Therapeutics (ALGS) shares rose about 19.9% in after-hours after the company said it received a $25 million upfront cash payment from Xiamen Amoytop Biotech under an exclusive Greater China licensing deal for pevifoscorvir sodium for chronic HBV. Aligos may receive up to $420 million in milestones plus royalties; the deal extends its cash runway into Q4 2026.
3 min readAligos Therapeutics (Nasdaq: ALGS) said it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for pevifoscorvir sodium for chronic hepatitis B. The drug also received China NMPA CDE Breakthrough Therapy Designation, which may enable priority NDA review. Aligos could earn up to $420M in milestones plus royalties; it keeps rights in the US, Europe, Japan, and other markets.
3 min readAligos Therapeutics (NASDAQ:ALGS) shares rose about 21% after hours after it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China licensing deal for pevifoscorvir sodium for chronic hepatitis B. Aligos can earn up to $420M milestones plus royalties; the drug also received China Breakthrough Therapy Designation.
3 min readAligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001799448 0001799448 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,
4 min readLake Street Capital began coverage of Aligos Therapeutics (NASDAQ:ALGS), assigning a “buy” rating and a $45.00 price target, according to MarketBeat Ratings. Other analysts cited mixed views, with Cantor “overweight” at $20 and Westpark “buy” at $48; MarketBeat shows a $38.50 consensus target. ALGS reported May 7 EPS of -$2.21 vs -$2.29 expected and revenue of $2.83M vs $0.25M.
3 min readAligos Therapeutics said it presented at the EASL 2026 congress positive results for pevifoscorvir sodium in chronic hepatitis B. The company reported Phase 1 long-term follow-up showing reduced HBV cccDNA, and Phase 2 B-SUPREME data indicating lower HBV/HBV RNA and HBV levels below 3,000 IU/mL in some HBsAg+ patients after 96 weeks monotherapy.
4 min readAligos Therapeutics reported its Q1 2026 business progress and financial results, highlighting the FDA's Fast Track Designation for its HBV drug, pevifoscorvir sodium, and a significant licensing deal with Amoytop for Greater China, including a $25M upfront payment. The company also announced an increase in Phase 2 clinical trial enrollment for pevifoscorvir sodium and the continuation of the B-SUPREME study after a positive interim analysis. Despite these clinical advancements and external funding, Aligos reported a net loss of $23.0 million for Q1 2026 and anticipates its current cash reserves will fund operations into Q4 2026.
3 min read
